Veltassa (Patiromer Calcium Sorbitex) Patent Expiration, LOE Window & CMS Spending

Veltassa (Patiromer Calcium Sorbitex) by Vifor: FDA Orange Book core substance LOE 2030-05-29 (last listed 2033-10-08), 0 AB generics, $192.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorVifor
FDA Application & PathwayN205739 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2030-05-29
Last Listed Patent or Exclusivity Date2033-10-08
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$192.3M
2024 Medicare Part D Spend$175.1M
2024 Medicaid Spend$17.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel